GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safety surveillance study of long-term pegvisomant treatment of patients with acromegaly. A noninterventional safety surveillance study in which safety and treatment outcomes of pegvisomant were evaluated on the basis of data collected during a 7-year period.
Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience / Cannavo, S; Bogazzi, F; Colao, Annamaria; De Marinis, L; Maffei, P; Gomez, R; Graziano, E; Monterubbianesi, M; Grottoli, S.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 38:10(2015), pp. 1099-109-1109. [10.1007/s40618-015-0289-4]
Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience
COLAO, ANNAMARIA;
2015
Abstract
GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safety surveillance study of long-term pegvisomant treatment of patients with acromegaly. A noninterventional safety surveillance study in which safety and treatment outcomes of pegvisomant were evaluated on the basis of data collected during a 7-year period.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
